-+ 0.00%
-+ 0.00%
-+ 0.00%

Nuvation Bio's Safusidenib Shows 81.5% Clinical Benefit Rate in Phase 2 Glioma Study

PUBT·11/16/2026 13:07:31
Listen to the news
Nuvation Bio's Safusidenib Shows 81.5% Clinical Benefit Rate in Phase 2 Glioma Study
  • Nuvation Bio presented updated Phase 2 safusidenib results at the Society for Neuro-Oncology annual meeting on Nov. 16, 2026.
  • Long-term findings showed sustained tumor shrinkage and durable disease control in patients with previously untreated grade 2 IDH1-mutant glioma.
  • Safety remained manageable, with no new safety signals; side effects were mostly low-grade, though some patients discontinued treatment.
  • The investigational drug is advancing through the pivotal Phase 3 SIGMA study following FDA Fast Track designation in August 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY95614) on November 16, 2026, and is solely responsible for the information contained therein.